Recent analysis of a clinical trial with 1,864 patients examined the occurrence of adverse advents grade 3/4 (severe/life threatening) in a comparison of treatments with oxaliplatintermterm and capecitabinetermterm versus bolus FU/LV (fluorocuracil/leucovorintermterm). Capecitabine is an oral fluoroprimidine (5-FUterm prodrug) while bolus FU/LV is an infusion therapy. Capecitabine requires less medical resources and lowers costs for administration. It has been show that oxaliplatin with FU/LV prolongs disease-free survival significantly in patients with stage II/III colon cancer (CC) as well as reducing the recurrence of CC by more than 20% compared to FU/LV alone.